The worldwide epidemic of type 2 diabetes - Causes and consequences;A 2-es típusú diabetes világméretu terjedésének okai és következményei

Lege Artis Medicinae

Volumn 16, Issue 2, 2006, Pages 105-113

  Jermendy, György ^a  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

Cardiovascular diseases; Insulin resistance; Metabolic syndrome; Obesity; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GLICLAZIDE; GLUCOSE; INSULIN; MULTIVITAMIN; ORAL ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; DRUG CONTRAINDICATION; DRUG INDICATION; EPIDEMIC; GLUCOSE INTOLERANCE; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESTYLE; MASS SCREENING; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; PATHOPHYSIOLOGY; PILL; PREVALENCE; REVIEW; RISK FACTOR; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 33644591284     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of diabetes epidemic. Nature 2001;414:782-7.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
4. Dunstan DW, Zimmet PZ, Welborn TA, Courten MP de, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829-34.
5. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health factors, 2001. JAMA 2003;289:76-9.
6. King H, Rewers M, WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:l57-77.
7. Zimmet PZ, King H, Taylor R, Raper LR, Balkau B, Borger J, et al. The high prevalence of diabetes mellitus, impaired glucose tolerance and diabetic retinopathy in Nauru - the 1982 survey. Diabetes Res 1984;1:13-8.
8. Bonnici F, Podar T, Sieradzki J, Strojek K. Epidemiology of diabetes in Central and Eastern Europe and the Mediterranean Region. Int J Postgr Train Med 2002;27:20-1.
9. World Health Organization. WHO Study Group on diabetes mellitus. Technical Report Series 727. Geneva: WHO; 1985.
10. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20: 1183-97.
11. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
13. Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose. Where is the evidence? Where is the logic? Diabetes Care 2004;27:592-5.
14. International Diabetes Federation. The IDF consensus wordlwide definition of the metabolic syndrome, www.idf.org/webdata/docs/ IDF_Metasyndrome_definition. Szöveghu magyar fordítás: Diabetologia Hungarica 2005;13:107-12.
15. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 2003;46:182-9.
16. Satman I, Yilmaz T, Sengul A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish Diabetes Epidemiology Study (TURDEP). Diabetes Care 2002;25:1551-6.
17. Józan P. Fordulat a halandóságban és az életkilátásokban, epidemiológiai korszakváltás Magyarországon? Orv Hetil 2003;144:451-60.
18. Magyar Diabetes Társaság Metabolikus Munkacsoportja (Halmos T, Hidvégi T, Jermendy Gy, Káplár M, Korányi L, Pados Gy, Paragh Gy, Zajkás G). A metabolikus szindróma definíciója, diagnosztikai kritériumrendszere és szurése. Orv Hetil 2002;143:785-8.
19. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation consensus workshop. Diabetes Care 2004;27:1798-811.
20. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-74.
21. Körner A, Madácsy L. Rising tide of type 2 diabetes mellitus and impaired glucose tolerance among Hungarian children and adolescents. Diabetologia Hungarica 2002;10(S2):22-7.
22. Webber J. Changing epidemiology of obesity - implications for diabetes. In: Obesity & Diabetes. Barnett AH, Kumar S (eds.). Chichester: John Wiley&Sons; 2004. p. 1-11.
23. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
24. Jermendy Gy. Metabolikus szindróma és az evidenciák. Metabolizmus 2004;2:179-84.
25. Jermendy Gy. Miért lett a centrális típusú elhízás a metabolikus szindróma nemzetközi diagnosztikai kritériumrendszerének alapvetó eleme? Metabolizmus. In press, 2006.
26. Korányi L. Az elhízás/diabetes endémia: diabesitas világjárvány. Orvostovábbképzo Szemle 2004;11:9-19.
27. Lowry R, Wechsler H, Galuska DA, Fulton JE, Kann L. Television viewing and its associations with overweight, sedentary lifestyle, and insufficient composition of fruits and vegetables among US high school students: Differences by race, ethnicity, and gender. J Sch Health 2002;72:413-21.
28. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-5.
29. International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004;11:3-8.
30. Flegal KM, Carroll MD, Ogden CI, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288: 1723-7.
31. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in over-weight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-32.
32. Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997;40:125-35.
33. Suba I, Halmos T, Kautzky L. Az egyes vizsgálati parametérek értéke a metabolikus x-szindróma diagnózisában és felkutatásában. Orv Hetil 1997;138:2407-411.
34. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.
35. Isomaa B, Almgreen P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
36. Jermendy Gy, Hetyési K, Bíró L, Hidvégi T. Prevalence of the metabolic syndrome in hypertensive and/or obese subjects. Diabetic Med 2004;21:805-6.
37. Reaven GM. The role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
38. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-63.
39. Han TS, Williams K, Sattar N, Hunt KJ, Lean ME, Haffner SM. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10:923-31.
40. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, et al. Predictors of the incident metabolic syndrome in adults. The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:788-93.
41. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 2000;21:697-738.
42. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684-99.
43. Gale EAM. The myth of the metabolic syndrome. Diabetologia 2005;48:1679-83.
44. Reaven GM. The metabolic syndrome: Requiescat in pace. Clin Chem 2005;51:931-8.
45. Grundy SM. The metabolic syndrome still lives. Clin Chem 2005; 51:1352-7.
46. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
47. Zimmet PZ, Alberti G. The metabolic syndrome: perhaps an etiologic mystery but far from a myth. Where the International Diabetes Federation stand? Medscape Diabetes & Endocrinology 2005;7:10.
48. Ford SE. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769-78.
49. International Diabetes Federation IGT/IFG Consensus Statement. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Med 2002;19:708-23.
50. Murphy NE, Macintyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006;27:96-106.
51. Dean H, Flett B. Natural history of type 2 diabetes diagnosed in childhood: long term follow-up in young adult years. Diabetes 2002;51(S1):A24.
52. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
53. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
54. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
55. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24.
56. Járay Z. Az endocannabinoid rendszer szerepe a táplálékfelvétel szabályozásá ban és az elhízás létrejöttében. Metabolizmus 2005;3:146-49.
57. Wenger T. Az endocannabinoid rendszer. Metabolizmus 2005;3: 232-5.
58. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
59. Després JP, Golay A, Sjöström L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.